150 related articles for article (PubMed ID: 20018297)
21. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
[TBL] [Abstract][Full Text] [Related]
22. Immunolocalization of liver receptor homologue-1 (LRH-1) in human breast carcinoma: possible regulator of insitu steroidogenesis.
Miki Y; Clyne CD; Suzuki T; Moriya T; Shibuya R; Nakamura Y; Ishida T; Yabuki N; Kitada K; Hayashi S; Sasano H
Cancer Lett; 2006 Nov; 244(1):24-33. PubMed ID: 16427184
[TBL] [Abstract][Full Text] [Related]
23. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
24. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
[TBL] [Abstract][Full Text] [Related]
25. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.
Lindemann K; Resau J; Nährig J; Kort E; Leeser B; Annecke K; Welk A; Schäfer J; Vande Woude GF; Lengyel E; Harbeck N
Histopathology; 2007 Jul; 51(1):54-62. PubMed ID: 17593080
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of HER-2/neu expression in patients with ductal carcinoma in situ.
Stackievicz R; Paran H; Bernheim J; Shapira M; Weisenberg N; Kaufman T; Klein E; Gutman M
Isr Med Assoc J; 2010 May; 12(5):290-5. PubMed ID: 20929083
[TBL] [Abstract][Full Text] [Related]
27. Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer.
Nakamura Y; Yasuoka H; Tsujimoto M; Yang Q; Imabun S; Nakahara M; Nakao K; Nakamura M; Mori I; Kakudo K
Clin Cancer Res; 2003 Nov; 9(14):5313-7. PubMed ID: 14614015
[TBL] [Abstract][Full Text] [Related]
28. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
29. p27KIP-1, cyclin A and cyclin D1 protein expression in ductal carcinoma in situ of the breast: p27KIP-1 correlates with hormone receptor status but not with local recurrence.
Millar EK; Tran K; Marr P; Graham PH
Pathol Int; 2007 Apr; 57(4):183-9. PubMed ID: 17316413
[TBL] [Abstract][Full Text] [Related]
30. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer.
Serrano-Olvera A; Dueñas-González A; Gallardo-Rincón D; Candelaria M; De la Garza-Salazar J
Cancer Treat Rev; 2006 May; 32(3):180-90. PubMed ID: 16483720
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical analysis of expression of a 65 kDa oncofetal protein (p65), epidermal growth factor receptor (EGFR), oncogene c-erb B2 and tumor suppressor gene p53 protein products in breast cancer patients.
Niewiadomska H; Mirowski M; Stempień M; Błoński JZ; Czyz W; Switalska J; Matyga E; Hanausek M; Wierzbicki R
Neoplasma; 2000; 47(1):8-14. PubMed ID: 10870681
[TBL] [Abstract][Full Text] [Related]
32. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Xie F; Wang Q; Chen Y; Gu Y; Mao H; Zeng W; Zhang X
Pathol Res Pract; 2010 Nov; 206(11):735-9. PubMed ID: 20634005
[TBL] [Abstract][Full Text] [Related]
33. Cyclo-oxygenase type 2 is dysregulated in breast ductal carcinoma in situ and correlates with poor outcome.
de la Torre J; Sabadell MD; Rojo F; Lirola JL; Salicru S; Reventos J; Ramón y Cajal S; Xercavins J
Eur J Obstet Gynecol Reprod Biol; 2010 Jul; 151(1):72-6. PubMed ID: 20227160
[TBL] [Abstract][Full Text] [Related]
34. Study of HER2/neu status in Qatari women with breast carcinoma.
Rasul KI; Mohammaed K; Abdalla AS; Chong-Lopez A; Ahmad MA; Al-Homsi MU; Al-Hassan AM; Al-Alosi AS; Bener A
Saudi Med J; 2003 Aug; 24(8):832-6. PubMed ID: 12939666
[TBL] [Abstract][Full Text] [Related]
35. Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast.
Rody A; Diallo R; Poremba C; Speich R; Wuelfing P; Kissler S; Solbach C; Kiesel L; Jackisch C
Oncol Rep; 2004 Oct; 12(4):695-9. PubMed ID: 15375487
[TBL] [Abstract][Full Text] [Related]
36. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
[TBL] [Abstract][Full Text] [Related]
37. Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression.
Logullo AF; Nonogaki S; Pasini FS; Osório CA; Soares FA; Brentani MM
Oncol Rep; 2010 Feb; 23(2):313-20. PubMed ID: 20043090
[TBL] [Abstract][Full Text] [Related]
38. Inclusion of tumor biology molecular markers to improve the ductal carcinoma in situ ipsilateral breast tumor recurrence nomogram predictability.
Ballehaninna UK; Chamberlain RS
J Clin Oncol; 2011 Feb; 29(4):e97-8; author reply e99. PubMed ID: 21172894
[No Abstract] [Full Text] [Related]
39. D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma.
Rabban JT; Chen YY
Hum Pathol; 2008 Feb; 39(2):175-83. PubMed ID: 18206495
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T
Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]